Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Shares Outstanding (Diluted Average) (2022 - 2025)

Barinthus Biotherapeutics' Shares Outstanding (Diluted Average) history spans 4 years, with the latest figure at $40.5 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 3.0% year-over-year to $40.5 million; the TTM value through Dec 2025 reached $40.5 million, up 3.0%, while the annual FY2025 figure was $40.5 million, 3.0% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $40.5 million in Q4 2025 per BRNS's latest filing, roughly flat from $40.4 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $40.5 million in Q4 2025 to a low of $38.0 million in Q1 2023.
  • Average Shares Outstanding (Diluted Average) over 4 years is $39.1 million, with a median of $38.8 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Diluted Average): rose 0.38% in 2023, then rose 3.85% in 2025.
  • A 4-year view of Shares Outstanding (Diluted Average) shows it stood at $38.2 million in 2022, then increased by 0.57% to $38.4 million in 2023, then grew by 2.51% to $39.3 million in 2024, then increased by 3.0% to $40.5 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Shares Outstanding (Diluted Average) are $40.5 million (Q4 2025), $40.4 million (Q3 2025), and $40.3 million (Q2 2025).